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COMMENTARY
Adipose stromal cells promote the transition of colorectal cancer cells toward a 
mesenchymal-like phenotype
Simone Di Franco and Giorgio Stassi
Department of Surgical Oncological and Stomatological Sciences (DICHIRONS), University of Palermo, Palermo, Italy
ABSTRACT
Colon cancer progression is among the risks that increase with obesity. We have recently unveiled the 
molecular mechanism by which adipose tissue-released molecules, HGF and IL-6, make colorectal cancer 
(CRC) cells acquiring mesenchymal traits. Targeting of adipose-derived factors abrogate the metastatic 
potential of CRC stem cells (CR-CSCs) in obese patients.
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Author’s comment
Although showing a slow decline in incidence, colorectal can-
cer (CRC) still represents the third most common cause of 
cancer-related death.1 Despite the great effort dedicated to 
CRC research, which led to an improved survival rate in the 
last decades, the complex molecular machinery involved in the 
promotion of tumorigenesis and metastatic process is still not 
fully defined. In the last years, the role of tumor microenviron-
ment (TME), including adipose tissue, the biggest endocrine 
organ, emerged as key player favoring the initiation and pro-
gression of tumor disease, due to the released factors that 
support a chronic inflammation. It has been demonstrated 
that obesity, whose prevalence is increasing worldwide, con-
tributes to the increase of cancer incidence and to up to 20% of 
cancer-related deaths.2 We have demonstrated that a small cell 
population, which share many biological features with normal 
stem cells, called cancer stem cells (CSCs), whose number and 
phenotype are finely regulated by the TME,3–5 sustains the 
tumor growth. This cell subset has been found to be highly 
heterogeneous, whose heterogeneity influences the clinical out-
come and response to chemo- and targeted-therapy. Guinney 
et al. have identified four transcriptional signatures that classify 
CRC into four consensus molecular subtypes (CMSs). 
Although each CMS has been associated with distinguishing 
features and clinical perspective, specifically CMS1, immune; 
CMS2, epithelial; CMS3, metabolic; CMS4, mesenchymal,6 the 
effect of CRC TME on CMS plasticity is still unclear.
We demonstrated that HGF and IL-6 among the factors 
secreted by visceral adipose stromal cells (V-ASCs), expand 
the CRC stem cell (CR-CSC) compartment identified by the 
expression of CD44V6.7 Interestingly, we noticed that 
CD44V6+ cells release: i) some of the neurotrophins, as 
nerve growth factor (NGF) and Neurotrophin-3 (NT-3), 
favoring the recruitment and growth of neighboring 
V-ASCs, ii) and the Vascular-Endothelial Growth Factor 
(VEGF) that induces the endothelial transdifferentiation of 
V-ASCs, thus setting a favorable environment for cancer cell 
dissemination. Interestingly, the presence of V-ASCs, within 
the tumor, makes cancer cells acquire an invasive phenotype, 
in line with their reprogramming from CMS2 toward CMS4- 
like transcriptomic profile. V-ASCs microenvironmental fac-
tors foster the activation of Signal Transducer And Activator 
Of Transcription 3 (STAT3), which in turn downregulates 
miR-200a expression, thus leading to increased expression 
levels of Zinc finger E-box-binding homeobox 2 (ZEB2), 
a master epithelial–mesenchymal transition (EMT) regulator 
(Figure 1). Targeting STAT3 pathway abrogates the meta-
static dissemination driven by V-ASCs.
Taken together, these findings reveal a new molecular 
mechanism by which visceral adipose tissue positively regulate 
the mesenchymal phenotype of CRC cells, by increasing their 
metastatic potential. In particular, adipose-derived factors, 
released in TME of obese patients, reprogram CMS2 CRC 
cells toward a hybrid epithelial/mesenchymal (CMS2/CMS4) 
cell phenotype, endowed with boosted tumorigenic and meta-
static capacity. This observation is in line with the identifica-
tion of CRC patients classified as mixed phenotype, which are 
characterized by a “hybrid” epithelial-mesenchymal (E/M) 
phenotype,8,9 and an undefined clinical outcome. To note, 
the presence of a E/M state in cancer cells has been recently 
associated with the concomitant retainment of cancer stemness 
and tumor initiation abilities.10
If we will be able to define a specific molecular signature, 
aimed at the identification of obese CMS2 CRCs who might 
progress aggressively, we could identify eligible patients for an 
adjuvant therapy regimen.
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Figure 1. EMT-regulating crosstalk between adipose stromal cells and colorectal cancer cells in obese CRC patients. The paracrine activity of visceral adipose stromal 
cells (V-ASCs) boosts the proliferative and invasive capacity of nearby colorectal cancer (CRC) cells through the release of HGF and IL-6. These visceral adipokines drive 
the transition of epithelial (CMS2) CRC cells toward a highly aggressive hybrid epithelial/mesenchymal (CMS2/CMS4) subtype. Targeting of the pathways activated by 
microenvironmental adipokines restrain the metastatic potential of CRC cells.
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